Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for Axsome Therapeutics in a research report issued ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Axsome Therapeutics, Inc. (NASDAQ:AXSM) stands against the ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Halozyme (HALO – Research Report), Walgreens Boots Alliance ...

Axsome Therapeutics' stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth, but I maintain a "sell" rating. Despite Auvelity's revenue growth, significant ...

Good morning, and welcome to the Axsome Therapeutics' fourth quarter and full year 2024 conference call. Currently, all participants are in listen-only mode. Later, there will be a question-and ...

Axsome Therapeutics, a biopharmaceutical company targeting central nervous system (CNS) disorders, develops novel therapies for depression, narcolepsy, and other CNS conditions. Its current ...

In this article, we are going to take a look at where Axsome Therapeutics, Inc. (NASDAQ:AXSM) stands against other best performing healthcare stocks so far in 2025. Despite the ongoing craze ...

Significant R&D investment of $55 million highlights a focus on pipeline development. Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than ...